Stockreport

Actuate Therapeutics: Looking To Make An Impact In Pancreatic Cancer [Seeking Alpha]

Actuate Therapeutics, Inc. - Common stock  (ACTU) 
PDF The company's phase 2 trial showed improved survival rates with elraglusib, but the control arm underperformed, raising questions about future phase 3 results. ACTU's [Read more]